Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
about
Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib.Pazopanib in the treatment of soft tissue sarcomaSystematic comparative protein expression profiling of clear cell renal cell carcinoma: a pilot study based on the separation of tissue specimens by two-dimensional gel electrophoresis.Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinibTumor necrosis factor receptor expression and signaling in renal cell carcinomaFeasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.Development of second-generation VEGFR tyrosine kinase inhibitors: current status.The prospects of pazopanib in advanced renal cell carcinoma.Stratification of clear cell renal cell carcinoma by signaling pathway analysis.5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma.The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy.Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertensionDCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitroStrategies to optimize the use of targeted agents for tumor therapy.MET Inhibition in Clear Cell Renal Cell Carcinomagamma-Secretase: a multifaceted regulator of angiogenesisImmunotherapeutic strategies to target prognostic and predictive markers of cancer.Prognostic biomarkers of renal cell carcinoma: Recent advances.Increased intratumoral fluorothymidine uptake levels following multikinase inhibitor sorafenib treatment in a human renal cell carcinoma xenograft modelCombination of antiangiogenesis with chemotherapy for more effective cancer treatment.Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma.Obesity and renal cell carcinoma: epidemiology, underlying mechanisms and management considerations.Renal Cell Carcinoma Metastatic to the Scalp.Pazopanib: an antiangiogenic drug in perspective.Is there a role for presurgical therapy for renal cell carcinoma?Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience.A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.Anti-angiogenic drug discovery: lessons from the past and thoughts for the future.Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma.Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring.Circulating endothelial cells and their subsets: novel biomarkers for cancer.In Vitro and In Vivo Evaluation of Targeted Sunitinib-Loaded Polymer Microbubbles Against Proliferation of Renal Cell Carcinoma.Cardiotoxicity associated with targeted cancer therapies.Inhibition of retinopathy of prematurity in rat by intravitreal injection of sorafenib.A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts.Neurosensory retinal detachment due to sunitinib treatment.Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity.
P2860
Q27853203-1D5BB5C4-9D96-4550-B3D9-87FF1DA3CF85Q28269229-60BB2AD4-0C70-41B9-9508-88F247726E87Q30319002-80F718A3-20E1-4246-92F3-D7F4D3A2126EQ33400232-741FBD51-C9C8-440C-9E18-F0A7E98BE036Q34033309-F52E4AB1-A7DE-4492-BD78-EBD9958BE730Q34041554-7B7665B7-257C-4881-B87F-ED3E2E24B003Q34139923-50D9C32C-58FD-4F55-BD0F-9FC0899CAFA7Q34616440-1C185578-09F0-4FEA-99F0-18C305694B86Q34656393-3E005B79-886F-4EE7-B1EB-2D41D848ABC6Q35103884-6EFDB4B1-00D5-40BB-97CD-29B3618D3CE8Q36084341-F303F891-7440-440D-9EED-9A7A3448128CQ36204010-33B8C2B1-AE21-4901-AA28-7B7CD18E25BEQ36739882-B4AB4D47-A880-442D-8404-C2EDB95D072FQ36746141-B4BDADB4-2650-4E3F-8695-57E0D903D25CQ37060553-71CC9439-0386-43AF-AAFD-38A596A0D99EQ37067981-1EA30DE9-D131-4F8A-A983-971E4E61FD94Q37081791-46D30E50-8979-4A93-B9DE-01ABA4D4CE24Q37126006-1DF41E61-B177-41AA-9798-BFA0BFA117D8Q37197505-7F592FF9-8344-4E82-879D-19B2E0005BD3Q37211631-5A4F1ACB-D3F3-4790-A546-BCEFA66A1718Q37346912-B8E8E874-3FFA-47B5-80F4-5C04A0419A7CQ37508022-327189AB-B84D-4D3D-A7F9-1771D172E973Q37546055-DF00F516-C173-41CF-A5C8-18459E280287Q37579707-7BDEA535-E884-4978-AECD-79115DD7FBF4Q37630567-EB3B809A-A524-4C51-9087-C4E1B5EC786CQ37765582-746572EB-8ACE-4859-9C6E-958832114951Q37905601-406B3F1B-AD61-4D44-AC0C-8D4C34EBB4BEQ37976467-B2682C0B-0B4D-4FA2-8554-1EA8CF570206Q38020234-4D9080F3-7825-4043-9C68-E2946397D94FQ38048822-12D905F5-1BBF-449B-AB85-060AC7CBFEBDQ38664221-4D7874DA-AFAC-495C-A2AC-CD4BFC0E02A1Q38672972-0D700518-E655-4086-BE8F-FFA7E07F449FQ38790666-C7D89D1E-D33D-4537-9918-E83C0EEDBFF5Q38819670-7E2F0C98-7B31-4687-80C4-C7B07BACCA04Q39023752-8802BACB-BC47-411B-AA55-94A93809098DQ39473604-40D6D20B-8957-4A53-92E2-214D2AE980AFQ39474834-A4C5BB06-F553-4E38-9BC1-C5CB1A6605F4Q39608929-AB666D6B-6E94-4699-988F-FB8BF0A97375Q42917003-D3117C33-6532-42A8-88DC-B94AF0DB128BQ42975694-35682F30-637F-4C27-8D52-5F2A40EF6C31
P2860
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Vascular endothelial growth fa ...... status and future directions.
@ast
Vascular endothelial growth fa ...... status and future directions.
@en
type
label
Vascular endothelial growth fa ...... status and future directions.
@ast
Vascular endothelial growth fa ...... status and future directions.
@en
prefLabel
Vascular endothelial growth fa ...... status and future directions.
@ast
Vascular endothelial growth fa ...... status and future directions.
@en
P1476
Vascular endothelial growth fa ...... status and future directions.
@en
P2093
Brian I Rini
P304
P356
10.1158/1078-0432.CCR-06-1989
P407
P577
2007-02-01T00:00:00Z